Clinical outcomes of immune checkpoint inhibitors in unresectable or metastatic combined hepatocellular–cholangiocarcinoma
Yoon Jung Jang, Eo Jin Kim, Hyung‐Don Kim, Kyu‐pyo Kim, Min‐Hee Ryu, Sook Ryun Park, Won‐Mook Choi, Danbi Lee, Jonggi Choi, Ju Hyun Shim, Kang Mo Kim, Young‐Suk Lim, Han Chu Lee, Baek‐Yeol Ryoo, Changhoon Yoo
Topics & Concepts
MedicineNivolumabInternal medicineAtezolizumabIpilimumabPembrolizumabResponse Evaluation Criteria in Solid TumorsGastroenterologyAdverse effectHepatocellular carcinomaHepatitis C virusHematologyOncologyCancerSurgeryPhases of clinical researchClinical trialImmunotherapyImmunologyVirusCholangiocarcinoma and Gallbladder Cancer StudiesHepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers